News

Detailed price information for Harvest Eli Lilly Enhanced High Income S (LLHE-T) from The Globe and Mail including charting and trades.
"Driven by Rising Chronic Disease Burden and Breakthrough FDA Approvals, Biopharmaceutical Market Surges with Demand for Monoclonal Antibodies, Gene and Cell Therapies, and Innovative Vaccines" BOSTON ...
This might be the most critical week for investors in years. In fact, in over two decades of investing, and more than a decade as a professional analyst, I’ve never seen a single week with this many ...
Today, more than 2 in 3 physicians are using health AI—up 78% from less than 2 years ago. As doctors increasingly adopt these technologies, expect even more growth opportunities for investments in ...
Three Motley Fool contributors have picked surprisingly underrated stocks to buy right now. Here's why they chose big pharma ...
New Wegovy prescriptions have increased by about 33% since May 22, when a U.S. Food and Drug Administration ban on so-called ...
The U.S. FDA ban on compounded versions of Novo Nordisk's Wegovy has increased its prescriptions by 33%. Despite this, ...
Novo Nordisk’s weight loss drug, Wegovy, is experiencing a surge in new prescriptions following a US ban on its copycat ...